Description: MultiCorp International, Inc is committed itself to the further development of the patented migraine medicine the company owns a significant percentage of. The company has received information from the U.S. Food and Drug Administration that provides the company with a clear path to further the development of the drug to bring to market. The company is currently looking to partner with a pharmaceutical company that can assist the company in bringing the migraine medicine to market. For further information please contact them at info@multicorpinternational.com
Home Page: multicorpinternationalinc.com
5308 Derry Ave
Agoura Hills,
CA
91301
United States
Phone:
866 411 6242
Officers
| Name | Title |
|---|---|
| Mr. Paul D. Lisenby | Chairman & CEO (Leave of Absence) |
| Mr. David Gustafson | Interim Chief Exec. Officer |
| Mr. Ben Friedman | Pres and Director |
| Mr. Tony Platt | Chief Marketing Officer |
| Mr. Kia Mohammadi | Chief Risk Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |